Phase 1 N=47 Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: AUC(0-1h,ss) of Olodaterol — 4.67; 4.15 pg*h/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=62 Muscle Perfusion and Protein Metabolism in Elderly
Aging
Primary: Mixed Muscle Fractional Synthesis Rate (FSR) — 0.061; 0.070; 0.066; 0.070 Fractional Synthesis Rate (pecent/hour)
Phase 1 N=72 Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.
Hypertension and Chronic Heart Failure
Primary: Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Single Ascending Dose (SAD) Period — 28; 0; 0; 0 % of subject…
Phase 1 N=12 Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment
Severe Hepatic Impairment
Primary: AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine — 166.955; 188.663 ng*hr/mL
Phase 1 N=31 A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Cytomegalovirus Infections
Primary: Area Under The Observed Plasma Concentration-Time Curve Between Dosing Intervals AUC(0-tau) — 66.2; 54.1 h*mcg/mL
Phase 1 N=68 Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
Healthy Volunteer
Primary: AUC of AZD9291 — 6690; 6269 nM.h
Phase 1 N=36 Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride
Healthy
Primary: Cmax — 31.27; 35.50 ng/mL — p=0.0082
Phase 1 N=8 A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Number of Participants Who Demonstrated Acute Adverse Events Following Infusion — 0; 0 participants
Phase 1 N=38 A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar
Healthy Volunteer
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Aleglitazar — 98.5; 113; 151 hours (h)*nanogram (ng)/milliliter (mL)
Phase 1 N=74 Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics
Parkinson's Disease (PD)
Primary: Cmax - Maximum Plasma Concentration of Levodopa (Levodopa/Carbidopa) — 966.6; 1026.8; 1097.9; 1019.7 ng/mL
Phase 1 N=32 Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)
Type 2 Diabetes (T2D)
Primary: Number of Participants Experiencing an Adverse Event (AE) — 12; 2; 4; 2 Participants
Phase 1 N=20 Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
Parkinson's Disease (PD)
Primary: Cmax - Maximum Observed Plasma Concentration (BIA 9-1067 + Warfarin) — 196 ng/mL
Phase 1 N=18 Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa
Parkinson Disease
Primary: Cmax - Maximum Observed Plasma Concentration (L-DOPA) — 1070; 1105; 1198 ng/mL
Phase 1 N=30 Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib — 0; 0; 0; 0 participants
Phase 1 N=15 Study to Determine if Fibrin Affects the Ability of a Wound to Heal
Effect of Test Articles on the Healing of a Wound Artificially Induced by Liquid Nitrogen Spray
Primary: Time (in Days) to Wound Closure (Healing) Defined as Skin Re-epithelialization, Without Drainage or Dressing Requirements. — 14.4; 13.3 days to wound closure — p=.3393